Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Stage IV non-small cell lung cancer (NSCLC) treatment relies on identifying oncogene driver mutations like EGFR, ALK, ROS-1, and BRAF V600.
• Immune checkpoint inhibitors (CPIs) and small molecule therapies (tyrosine kinase inhibitors, TKIs) have significantly advanced NSCLC treatment.

Purpose of the Study:

• To review recent findings on combining CPIs and TKIs in stage IV NSCLC.
• To detail the significant toxicities and potential mechanisms associated with concurrent and sequential combination therapies.
• To emphasize the importance of molecular profiling for optimizing treatment sequencing and minimizing toxicity.

Main Methods:

• Literature review of recent studies on combination CPI and TKI therapy in stage IV NSCLC.
• Analysis of reported toxicities and their underlying mechanisms.
• Discussion of treatment sequencing strategies based on emerging therapeutic targets.

Main Results:

• Combination CPI and TKI therapies show promise but are associated with significant toxicities.
• Both concurrent and sequential administration approaches have distinct toxicity profiles and mechanisms.
• Optimal sequencing of therapies is crucial for maximizing efficacy and managing adverse events.

Conclusions:

• Combining CPIs and TKIs represents a significant development in stage IV NSCLC treatment.
• Understanding and managing treatment-related toxicities is paramount.
• Comprehensive molecular profiling, especially in stage III NSCLC, is essential for guiding safe and effective treatment sequencing.